New pill aims to keep narcolepsy patients awake and safe from sudden falls
NCT ID NCT07455383
First seen Mar 11, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tests an experimental tablet called ALKS 2680 in 150 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants receive either the drug or a placebo for 12 weeks. The goal is to see if the drug helps people stay awake longer and reduces cataplexy episodes. This is a phase 3 trial, meaning it is one of the final steps before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alkermes Investigational Site
RECRUITINGBrandon, Florida, 33511, United States
-
Alkermes Investigational Site
RECRUITINGMacon, Georgia, 31210, United States
-
Alkermes Investigational Site
RECRUITINGLansing, Michigan, 48911, United States
-
Alkermes Investigational Site
RECRUITINGSt Louis, Missouri, 63123, United States
-
Alkermes Investigational Site
RECRUITINGCincinnati, Ohio, 45245, United States
-
Alkermes Investigational Site
RECRUITINGWyomissing, Pennsylvania, 19610, United States
-
Alkermes Investigational Site
RECRUITINGColumbia, South Carolina, 29201, United States
-
Alkermes Investigational Site
RECRUITINGAustin, Texas, 78731, United States
-
Alkermes Investigational Site
RECRUITINGSugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.